Home > Boards > US OTC > Computers - Hardware >

GeoVax Labs Inc. (GOVX)

Add GOVX Price Alert      Hide Sticky   Hide Intro
Moderator: Tonyeight, 02opida, pb_trading, bula, maz1978 , tymerz
Search This Board: 
Last Post: 10/15/2019 3:09:39 PM - Followers: 269 - Board type: Free - Posts Today: 80

as we have many discussion here about whether convertible is done or not, here are the calculation based on official trading volumes as reported by yahoofinance , from 1. October till now (after Geovax last update). The calculations are based on the volume and HIGHEST price per day (not 80% of price), given that ALL the volume would have come from conversion (which is almost impossible). 

11. October: volume 78.520.447,0000, highest price: 0,0020, USD value: 157.040,89
10. October: volume 67.022.024,0000, highest price: 0,0030, USD value 201.066,07
9. October: volume: 102.821.930,0000, highest price:0,0043, USD value: 442.134,30
8 October: volume: 60.294.478,0000, highest price:0,0027, USD value: 162.795,09
7. October: volume: 52.257.646,0000, highest price:0,0020, USD value: 104.515,29
1. October: volume: 48.591.000,0000, highest price:0,0100, USD value: 485.910,00

total USD: 1.553.461,65
total shares 409.507.525+95.627.584 million as reported for 30th Sep= approx. 505 million shares
if the assumptions to "all valume comes from conversion" were true, it is 50% of outstanding convertible, with more than 500 million outstanding shares by now.


AS OF 10/09/2019
will update as changes happen

Market Cap 432,689 (per OTCMarkets 10/08/2019)
A/S - 600M as stated in latest 8k and OTCMarkets (10/08/19)
O/S - 96M as stated in latest 8k - 136M as stated on OTCMarkets (10/08/19)
Float - 106M (per OTCMarkets 10/02/19)




GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology.

Our proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), and Emory University.  Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.

Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa) and Zika virus. We also have initiated programs to develop a vaccine to treat chronic Hepatitis B infection and to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases and we intend to pursue expansion of our product.

Our hemorrhagic fever vaccine program was initiated during 2014 in response to the Ebola epidemic in western Africa and with the goal of developing second generation monovalent and multivalent vaccines capable of preventing or containing future outbreaks of major hemorrhagic fever viruses indigenous to Africa. Our initial preclinical studies in rodents and nonhuman primates for our first vaccine candidate (Ebola-Zaire virus) have shown 100% protection against death after a single dose.

Our most advanced vaccines under development are designed to function against the clade B subtype of the HIV virus that is prevalent in the Americas and Western Europe. Our preventive clade B HIV vaccine has successfully completed Phase 2a human clinical testing has entered a follow-on clinical trial in 2017. Our clade B vaccine has shown outstanding safety and excellent, highly reproducible immunogenicity. We are extending our HIV vaccine effort to the most common virus subtype affecting the developing world, clade C. We also are investigating our HIV vaccines for their potential to contribute to combination therapies leading to a cure for HIV infections.
Our vaccine technology was developed in collaboration with researchers at Emory University, the NIH, and the CDC. The technology is exclusively licensed to us from Emory University. We also have nonexclusive licenses to certain patents owned by the NIH. Our hemorrhagic fever vaccines have been developed with technology licensed from, and in collaboration with, the NIH. Our immuno-oncology program is being developed pursuant to a research collaboration with the University of Pittsburgh. Our Zika vaccine program is in collaboration with University of Georgia and the CDC. Our HBV therapeutic program is in collaboration with Georgia State University and our malaria vaccine is being developed in collaboration with Burnet Institute in Australia.

Our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants awarded directly to us, in kind support in terms of animal experiments, as well as indirect support for the conduct of our human clinical trials. All of the human clinical trials of our preventative vaccines to date have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).


We know our work could affect the lives of millions worldwide, and we invite you to join our effort.



                                                                                  Technology Pipeline

Pipeline 03 16 2017 Final                                                                                                                                         



 Robert McNally, CEO of GeoVax Labs Inc.,

Watch This Informative 3 Minute Clip Presented By GeoVax President and CEO Robert McNally Giving An Overview Of The Company

#2 and #22  most influential vaccine scientist recently joined GOVX 

2016 Annual Letter to Shareholders 

We are committed to providing our shareholders with accessible, complete information about our company. Within this section of the website, you will find comprehensive stock information, corporate data and progress reports.

Investment Highlights

Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe)

Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV and Ebola animal models
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry

Global Vaccine Market Surging to More Than $70 Billion by 2024 thats 25x the size of medical marijuana industry of 3 Billion by 2020. 

Sabby Management own 5,518,000 shares 10%+ a major increase from 2016 to 2017
Emory University owns 10% 


Researcher: GOVX  Zika vaccine could be ready in two years







Zika vaccine developer names new chief scientific officer

                                                                                                        Jan 3, 2017, 10:51am EST Updated Jan 4, 2017, 11:59pm EST


Get Atlanta Newsletters and Aler
Morning Edition >> Afternoon Edit

Enter your email address

SignA Smyrna-based developer of vac                                                       A Smyrna-based developer of vaccines against Zika, Ebola, HIV and other infectious diseases has named a new chief scientific officer.

Farshad Guirakhoo was promoted to the C-suite role at GeoVax Labs Inc. from senior vice president of research and development, his title upon joining the company in 2015. The promotion was effective Jan. 1.

Farshad Guirakhoo

His predecessor as CSO, company co-founder Harriet L. Robinson, will remain as chief scientific officer emeritus, the company said in a statement.

"For the past year, Farshad has been a driving force behind the growth of our vaccine development pipeline, and we are pleased to expand his role at this critical time for our company," GeoVax President and CEO Robert T. McNallysaid in the statement. "In the role of Chief Scientific Officer, Dr. Guirakhoo will lead the scientific advancement of GeoVax's technology pipeline as the Company identifies and pursues new opportunities to address significant medical needs."

Robinson will continue to direct the company's HIV vaccine program and to serve as principal investigator on National Institutes of Health grants to GeoVax, McNally said. Robinson will also continue to serve as a member of the GeoVax Board of Directors.

Before joining GeoVax in 2015, Guirakhoo served in senior management and scientific roles with biotechnology companies included Vaxess Technologies, Hookipa Biotech, Sanofi Pasteur, Acambis Inc. and OraVax Inc. He earned his Ph.D. in virology at the Medical University of Vienna in Vienna, Austria, and he holds a M.Sc. degree in genetics and a B.Sc. degree in biology. His post-doctoral training included a stint at the Centers for Disease Control and Prevention'sDivision of Vector-Borne Infectious Diseases in Fort Collins, Colo. Guirakhoo has filed over 90 patent applications in his scientific career, according to the statement, and was instrumental in the development and commercialization of the Imojev Japanese encephalitis virus vaccine and the Dengvaxia vaccine for Dengue virus.

GeoVax Labs Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases. Its development programs are focused on vaccines against HIV, Zika, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa).

In February 2016, The University of Georgia and GeoVax announced a collaboration to develop and test a possible Zika virus vaccine. 

                                                                                                 Our Technology


Vaccines typically contain agents (antigens) that resemble disease-causing microorganisms. Traditional vaccines are often made from weakened or killed forms of the virus or from its surface proteins. Many newer vaccines use recombinant DNA (deoxyribonucleic acid) technology to generate vaccine antigens in bacteria or cultured cells from specific portions of the DNA sequence of the target pathogen. The generated antigens are then purified and formulated for use in a vaccine. The most successful of these purified antigens have been non-infectious virus-like particles (VLPs) as exemplified by vaccines for hepatitis B (Merck's Recombivax® and GSK's Engerix®) and Papilloma viruses (GSK's Cervarix®, and Merck's Gardasil®). Our approach uses recombinant DNA or recombinant viruses to produce VLPs in the person being vaccinated. In human clinical trials of our HIV vaccines, we have demonstrated that our VLPs, expressed in the cells of the person being vaccinated, are safe, yet elicit both strong and durable humoral and cellular immune response.

VLPs train the body's immune system to recognize and kill the authentic virus should it appear. VLPs also train the immune system to recognize and kill infected cells to control infection and reduce the length and severity of disease. One of the biggest challenges with VLP-based vaccines is to design the vaccines in such a way that the VLPs will be recognized by the immune system in the same way as the authentic virus would be. When VLPs for enveloped viruses like HIV, Ebola, Marburg  or Lassa fever are produced in vivo, they include not only the protein antigens, but also an envelope consisting of membranes from the vaccinated individual's cells. In this way, they are highly similar to the virus generated in a person's body during a natural infection. VLPs produced externally, by contrast, have no envelope; or, envelopes from the cultured cells (typically hamster or insect cells) used to produce them. We believe our technology provides distinct advantages by producing VLPs that more closely resemble the authentic virus, which in turn, allows the body's immune system to more readily recognize the authentic virus. By producing VLPs in vivo, we avoid potential purification issues associated with in vitro production of VLPs.

Ebola VLP                 HIV VLP

                    Ebola VLPs                                                                               HIV VLPs

Electron micrographs showing the VLPs elicited by GeoVax vaccines from human cells. Note that the Ebola VLPs on the left self-assemble into the rod-like shape of the authentic Ebola virus, while the HIV VLPs shown on the right take on the spherical shape of the authentic HIV virus. While below the resolution of these micrographs, both types of VLPs display what we believe to be the native form of their respective viral envelope glycoproteins which we believe is key to generating an effective immune humoral response.

Our MVA-VLP vector affords other unique advantages:

Safety: GeoVax/NIAID rMVA HIV vaccines have demonstrated outstanding safety in human clinical trials. Safety for MVA has been shown in more than 120,000 subjects in Europe, including immunocompromised individuals during the initial development of MVA and more recently with the development of MVA as a safer vaccine against smallpox.

Durability: GeoVax/NIAID rMVA technology raises highly durable vaccine responses, the most durable in the field of vectored HIV vaccines. We hypothesize that elicitation of durable vaccine responses is conferred on responding B cells by the vaccinia parent of MVA, which raises highly durable responses for smallpox.

Limited pre-existing immunity to vector: Following the eradication of smallpox in 1980, smallpox vaccinations subsequently ended, leaving all but those born before 1980 and selected populations (such as vaccinated laboratory workers, first responders) unvaccinated and without pre-existing immunity.

No need for adjuvants: MVA stimulates strong innate immune responses and does not require the use of adjuvants.

Thermal stability: MVA is stable in both liquid and lyophilized formats (> 6 years of storage).

Genetic stability and manufacturability: If appropriately engineered, MVA is genetically stable and can reliably be manufactured in either the established Chick Embryo Fibroblast cell substrate, or novel continuous cell lines that support scalability as well as greater process consistency and efficiency.

GOVX Zika Quicklinks: Breaking News

March ,2017           https://finance.yahoo.com/news/geovax-reports-vaccine-development-progress-130000086.html
March, 2017           https://www.geovax.com/news/entry/2017/03/20/geovax-reports-promising-results-for-zika-vaccine.html
March, 2017           https://www.geovax.com/news/entry/2017/03/14/geovax-announces-collaboration-with-american-gene-technologies-for-hiv-functional-cure.html
Febuary , 2017      https://www.geovax.com/news/entry/2017/02/02/geovax-media-and-presentation-update.html
January, 2017        https://www.geovax.com/news/entry/2017/01/23/geovax-announces-initiation-of-hiv-human-clinical-trial.html
January, 2017        https://www.geovax.com/news/entry/2017/01/17/geovax-to-collaborate-with-georgia-state-university-on-development-of-therapeutic-hepatitis-b-vaccine.html

October, 2016        GeoVax to Present at Upcoming Scientific Conferences on its Hemorrhagic Fever and Zika Vaccine Programs
June, 2016            GeoVax Discusses Zika Vaccine Development at American Society for Virology’s 35th Annual Meeting
June, 2016            GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting
May, 2016             GeoVax Presents at Zika Virus Scientific Conference
April, 2016            GeoVax Provides Update on Zika Vaccine Program
March, 2016         GeoVax Extends Research Collaborations on Zika Vaccine
March, 2016         GeoVax Applauds Passage of Senate Bill to Accelerate Development of Zika Virus Vaccines
February, 2016     GeoVax to Develop Vaccine Against Zika Virus

Long Speculation on GOVX's Zika Vaccine:

On November 6, 2016, 60 Minutes did a segment titled: The Zika Virus. The pieced highlighted a Zika vaccine platform that appears to be proving successful. The platform described is similar to that of GOVX' s Intellectual Property. Other connections include a CDC sponsorship & Emory University. No definitive evidence has been disclosed. 



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GOVX News: Current Report Filing (8-k) 04/30/2019 04:54:07 PM
GOVX News: Current Report Filing (8-k) 04/26/2019 04:22:37 PM
#9032  Sticky Note NEWS OUT =NEWS OUT =========NEWS OUT Tonyeight 10/15/19 09:10:24 AM
#8354  Sticky Note “HIV Vaccine Efforts Herald a New Era of BigJuan 10/10/19 10:04:21 AM
#9106   Fact of the matter is that with the hat12trick 10/15/19 03:20:03 PM
#9105   Show me one post of pumping army which Trompete 10/15/19 03:10:53 PM
#9104   Breakout, out of business Trompete 10/15/19 03:09:39 PM
#9103   I know. I was just looking for Jack_of_All_Trades 10/15/19 03:08:55 PM
#9102   And yet I am right all the time Trompete 10/15/19 03:08:36 PM
#9101   Just keep posting please, we need to crawl BigJuan 10/15/19 03:07:41 PM
#9100   Dude's a tool, not even worth responding to. stoflat 10/15/19 03:06:37 PM
#9099   Exactly, and the opportunity is here each day, Trompete 10/15/19 03:05:22 PM
#9098   Total crash not trash. In this case both Trompete 10/15/19 03:03:44 PM
#9097   Doesn’t pay to be a bitter loser from BigJuan 10/15/19 03:02:58 PM
#9096   Trompete: definite total trash, constipated anyway Jack_of_All_Trades 10/15/19 03:01:45 PM
#9094   Accept this, wo listed to me got paid Trompete 10/15/19 03:00:17 PM
#9093   $govx..ask is thinning out..bids are growing..looks ready to pop.. chris20 10/15/19 02:58:39 PM
#9092   LOL Accept This: those who listened to you BigJuan 10/15/19 02:57:48 PM
#9091   Geovax: possible total crash, anticipated anyway Trompete 10/15/19 02:56:24 PM
#9090   GOVX .0017 possible W formation breakout chart: sharky 10/15/19 02:53:53 PM
#9089   Geovax Stock is going nowhere. Accept this. Convertible Trompete 10/15/19 02:48:41 PM
#9088   Looks like she’s getting ready lots of accumulation GASTON3 10/15/19 02:40:59 PM
#9087   Exactly chart is primed for a nice move BigJuan 10/15/19 02:36:15 PM
#9086   Excellent post. GOVX should be back to Jack_of_All_Trades 10/15/19 02:27:14 PM
#9085   GOVX .0017? 50ma at .0221 RSI 28.78 sharky 10/15/19 02:23:05 PM
#9084   I think more likely MMs showing some green krisc62 10/15/19 01:52:58 PM
#9082   $govx..strong buys picking up again...excellent accumulation here... chris20 10/15/19 01:50:34 PM
#9081   Obviously. If they don't pay off Sabby in Trompete 10/15/19 12:49:43 PM
#9080   Agree, ceo is a moron to allow such krisc62 10/15/19 12:48:14 PM
#9079   No they don’t, CDEL has walked this ticker Thoth 10/15/19 12:46:04 PM
#9078   $govx..looks like a cross trade went through..seller done here? chris20 10/15/19 12:06:40 PM
#9077   Ok thanks for that opinion..... BigJuan 10/15/19 11:59:29 AM
#9076   CEO is the weakest element in Geovax puzzle...just Trompete 10/15/19 11:58:46 AM
#9075   LOL love how you think you know everything......either BigJuan 10/15/19 11:56:14 AM
#9074   Typical for such conferences. As CSO is going Trompete 10/15/19 11:51:09 AM
#9073   This is in process today. Big names at BigJuan 10/15/19 11:47:21 AM
#9072   1 thousand USD... it's joke Trompete 10/15/19 11:36:17 AM
#9070   Yep. Nice 600k ask hit just went through. stoflat 10/15/19 11:33:48 AM
#9069   $govx.. .0018 thin as paper here..looks ready to chris20 10/15/19 11:31:53 AM
#9068   Dodd was not able to secure real financing Trompete 10/15/19 11:30:11 AM
#9067   Really? Look how it worked.. diploma is not everything Trompete 10/15/19 11:28:17 AM
#9066   You and Trompete are way too funny... I Wisdom 10/15/19 11:24:34 AM
#9065   Nobody will buy here in only to help Trompete 10/15/19 11:24:13 AM
#9064   $govx hitting radars..think we see new faces soon ... chris20 10/15/19 11:13:45 AM
#9063   Accumulation picking up, faucet possibly off, just needs sharky 10/15/19 11:11:03 AM
#9062   They had many of them and as Dodd Trompete 10/15/19 11:07:45 AM
#9061   They participate at many conferences. It is not Trompete 10/15/19 11:05:54 AM
#9060   Let's break 0.002. GOVX lvhd 10/15/19 11:05:28 AM
#9059   $govx...break .0018 and thid could fly! chris20 10/15/19 11:03:17 AM
#9058   A piece of paper does not equate into stumpmoto 10/15/19 11:01:50 AM
#9057   Seller needs it back over a penny to convert? Doubledown75 10/15/19 10:57:04 AM
#9056   This scam not in the trips yet? Its Thoth 10/15/19 10:40:07 AM
#9055   Nice! Big jump in volume hitting the ask. stoflat 10/15/19 10:39:51 AM
#9054   $govx.. .0017 cleared with a bang!! chris20 10/15/19 10:38:11 AM